Cardiol Therapeutics Inc.

TSX:CRDL.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.36 +0.67%

+$0.00 today

Market cap
$164.10M
Beta
0.48
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $1.23High $2.33

Volume 0.08M

Average 0.12M

CRDL.TO Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Cardiol Therapeutics Inc.TSX: CRDL.TO

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -CA$27.56M, compared with -CA$23.14M a year earlier.

Context

  • Net debt amounted to 87.7% of total assets at the end of Q1 FY2026, down 3.2 pp from a year earlier.
  • Net debt grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -19.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$27.56M-29.4% QoQ
Last fiscal yearDec 2025
-CA$21.29M+30.0% YoY
Year agoMar 2025
-CA$23.14M-19.1% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.1%——
1 year+30.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

CAD · from the balance sheet

Latest · FY2025
(21.29M) CAD
Year-over-year change
+30.0%

Net Debt vs competitors

How CRDL.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -19.1% is the 2nd highest of 3, against a peer median of +6.1%.
  • Net debt amounts to 87.7% of total assets for CRDL.TO, versus a peer median of 24.5%.
CRDL.TO Competitors
Net Debt for CRDL.TO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
HLS.TOHLS Therapeutics Inc.Mar 2026$31.63M USD-31.3%-20.8%24.1%
MSCL.TOSatellos Bioscience Inc.Mar 2026-$18.71M USD+43.4%—24.9%
CRDL.TOCardiol Therapeutics Inc.Mar 2026-CA$27.56M CAD-19.1%—87.7%
Peer median (excluding CRDL.TO) —+6.1%-20.8%24.5%

Competitors are the stored peer set for CRDL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents83.9M59.47M34.93M30.58M21.42M
Short-term Investments00000
Net Receivables407.13K480.2K279.87K361.62K226.2K
Inventory00000
Other Current Assets00000
Total Current Assets87.14M61.44M36.15M31.67M23.5M
Property, Plant & Equipment (Net)356.49K295.74K337.06K195.59K118.09K
Goodwill00000
Intangible Assets379.25K294.8K210.36K00
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0(0)000
Total Non-current Assets735.74K590.54K547.42K195.59K118.09K
Total Assets87.88M62.03M36.7M31.86M23.62M
Account Payables4.19M8.35M06.98M0
Short-term Debt00033.01K0
Tax Payables00000
Deferred Revenue(4.19M)(8.35M)000
Other Current Liabilities7.33M1.4M8.3M(33.01K)5.62M
Total Current Liabilities11.57M9.8M8.3M7.01M5.66M
Long-term Debt00158.53K00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00(158.53K)00
Total Non-current Liabilities72.87K22.42K158.53K125.52K87.18K
Total Liabilities11.64M9.83M8.45M7.14M5.74M
Common Stock142.92M147.55M148.52M179.34M201.87M
Retained Earnings(83.52M)(114.45M)(142.58M)(179.25M)(213.07M)
Accumulated OCI4.18M3.52M3.52M00
Other Stockholders Equity0013600
Minority Interest00000
Total Equity76.24M52.2M28.25M24.73M17.88M
Total Debt117.58K72.87K158.53K158.53K125.52K
Net Debt(83.78M)(59.4M)(34.77M)(30.42M)(21.29M)

Cardiol Therapeutics Inc.

TSX:CRDL.TO

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.